8-K: Pulse Biosciences Appoints Liane Teplitsky as COO

Pulse Biosciences announced the appointment of Liane R. Teplitsky as Chief Operating Officer, effective April 8, 2026, and detailed her compensation package including stock options and RSUs tied to performance milestones.

Summary

• Pulse Biosciences has appointed Liane R. Teplitsky as its new Chief Operating Officer, effective April 8, 2026.
• Ms. Teplitsky's compensation includes an annual base salary of $525,000 and eligibility for an annual bonus of up to 70% of her base salary.
• She was granted a stock option to purchase 700,000 shares at $19.06 per share and 200,000 restricted stock units (RSUs).
• Vesting of the stock options and RSUs is tied to both time-based metrics and significant performance objectives, including market capitalization targets of $2 billion, $3 billion, and $5 billion, coupled with specific GAAP product revenue milestones ($100M, $200M, $330M).
• Dr. David Kenigsberg's role as Chief Medical Officer has been expanded to full-time to support the company's clinical strategy and the nPulse Cardiac Catheter Ablation System development.
• The company also announced inducement awards for two other new employees, totaling 7,700 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strategic strengthening of the executive team with experienced leadership and performance-aligned incentives, crucial for advancing the company's technology and commercialization efforts.

Positives

• Strengthens executive leadership with experienced COO Liane Teplitsky, who has a strong background in medtech, cardiovascular, and digital health.
• Expanded role for Dr. David Kenigsberg as full-time CMO enhances clinical strategy focus.
• Significant equity awards for the new COO are performance-based, aligning her incentives with long-term company value creation and market success.
• The appointment is expected to accelerate the development and commercialization of the nPulse Cardiac Catheter Ablation System.

Negatives

• The performance-based vesting of a substantial portion of the COO's equity awards means significant value realization is contingent on achieving ambitious market capitalization and revenue targets, which carry inherent risk.
• The employment is at-will, providing limited job security for the executive.

Risks

• Achievement of performance-based vesting for the COO's stock options and RSUs is contingent on reaching substantial market capitalization targets ($2B, $3B, $5B) and significant GAAP product revenue milestones ($100M, $200M, $330M), which are challenging and not guaranteed.
• The company's success is heavily reliant on the clinical and regulatory pathway for its nPulse technology, particularly the Cardiac Catheter Ablation System.
• The at-will nature of employment means termination can occur without cause.

Future Outlook

The appointment of Liane Teplitsky as COO and the expanded role of Dr. David Kenigsberg as CMO are intended to enhance the company's ability to accelerate the development and future commercialization of its nPulse technology, particularly the nPulse Cardiac Catheter Ablation System, and to achieve its clinical and regulatory objectives.

Management Comments

• "We are thrilled to welcome Liane to Pulse at such a consequential moment in the Company's development. She brings a wealth of relevant experience and a remarkable track record of building and scaling medtech businesses. Her operational and leadership experience will be instrumental in accelerating our strategic priorities with emphasis on the cardiac catheter development program. Together with Dr. Kenigsberg's expanded commitment to our clinical strategy, we have expanded the depth and capability of our executive team and are now optimally positioned to execute on our clinical and regulatory objectives."
• "What drew me to Pulse was the science; nanosecond PFA is a differentiated technology with the potential to meaningfully advance how atrial fibrillation is treated and patients respond. The clinical foundation is strong, the team is exceptional, and the Company is at an inflection point where focused execution can make a real difference. I am eager to contribute and look forward to working alongside the Pulse team to deliver on that potential for patients."

Industry Context

StockSavvy.ai notes that the appointment of a COO with a strong background in cardiovascular and electrophysiology therapies, like Liane Teplitsky, signals a strategic focus on advancing the commercialization of Pulse Biosciences' nPulse Cardiac Catheter Ablation System in a competitive medtech landscape.

Comparison to Industry Standards

• The equity grant structure for Liane Teplitsky, with a mix of time-based and performance-based vesting tied to significant market capitalization and revenue targets, aligns with common practices for attracting and retaining senior executives in growth-stage biotechnology and medical device companies.
• The performance milestones set for vesting (e.g., $2B market cap and $100M revenue) are ambitious and reflect the high-growth potential expected from companies developing novel medical technologies like nsPFA, though specific industry benchmarks for such early-stage revenue targets are highly variable.
• The base salary of $525,000 and bonus potential of 70% are within the typical range for a Chief Operating Officer at a publicly traded company of Pulse Biosciences' size and sector, though compensation can vary significantly based on location and specific company stage.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced COO and performance-based equity grants are intended to drive long-term shareholder value, contingent on achieving significant growth milestones.
• Employees: The addition of a seasoned executive may bring new operational efficiencies and strategic direction, potentially impacting team structures and priorities.
• Management: The performance-based equity for the COO aligns executive incentives with company performance, potentially increasing motivation and focus on key objectives.

Next Steps

• Liane R. Teplitsky will oversee Clinical, Regulatory, Quality, and Commercial functions.
• Dr. David Kenigsberg will continue to lead the company's clinical strategy, particularly the IDE pivotal clinical study for the nPulse Cardiac Catheter System.
• The company aims to accelerate the development and future commercialization of its nPulse technology.

Key Dates

Recommendation

The filing announces a key executive appointment and compensation details, which is a standard operational update. While the addition of an experienced COO is positive, the core business and future outlook remain largely unchanged by this specific filing. The performance-based equity is a good sign for alignment, but the actual achievement of these ambitious targets is yet to be seen. Therefore, a 'hold' recommendation is appropriate pending further operational and clinical progress.

Keywords

Pulse Biosciences, Liane Teplitsky, Chief Operating Officer, COO Appointment, nPulse technology, nsPFA, Cardiac Catheter Ablation System, Equity Awards